高级检索
当前位置: 首页 > 详情页

The emerging field of oncolytic virus-based cancer immunotherapy

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Hematology andHematopoietic Cell Transplantation,City of Hope National Medical Center,Los Angeles, CA 91010, USA [2]Laboratory of Molecular Oncology,Frontiers Science Center for Diseaserelated Molecular Network, State KeyLaboratory of Biotherapy and CancerCenter, West China Hospital, SichuanUniversity, Chengdu 610041, PR China [3]Harvey Cushing Neuro-OncologyLaboratories, Department ofNeurosurgery, Brigham and Women'sHospital, Harvard Medical School,Boston, MA 02115, USA [4]Hematologic Malignancies ResearchInstitute, City of Hope National MedicalCenter, Los Angeles, CA 91010, USA [5]Comprehensive Cancer Center, City ofHope, Los Angeles, CA 91010, USA [6]Department of Immuno-Oncology,Beckman Research Institute, LosAngeles, CA 91010, USA
出处:
ISSN:

摘要:
Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with cancers resistant to traditional therapies. Natural or genetically modified OVs are multifaceted tumor killers. They directly lyse tumor cells while sparing normal cells, and indirectly potentiate antitumor immunity by releasing antigens and activating inflammatory responses in the tumor microenvironment. However, some limitations, such as limited penetration of OVs into tumors, short persistence, and the host antiviral immune response, are impeding the broad translation of oncolytic virotherapy into the clinic. If these challenges can be overcome, combination therapies, such as OVs plus immune checkpoint blockade (ICB), chimeric antigen receptor (CAR) T cells, or CAR natural killer (NK) cells, may provide powerful therapeutic platforms in the clinic.Copyright © 2022 Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2023]版
大类 | 1 区 医学
小类 | 2 区 肿瘤学
第一作者:
第一作者机构: [1]Department of Hematology andHematopoietic Cell Transplantation,City of Hope National Medical Center,Los Angeles, CA 91010, USA [2]Laboratory of Molecular Oncology,Frontiers Science Center for Diseaserelated Molecular Network, State KeyLaboratory of Biotherapy and CancerCenter, West China Hospital, SichuanUniversity, Chengdu 610041, PR China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Hematology andHematopoietic Cell Transplantation,City of Hope National Medical Center,Los Angeles, CA 91010, USA [4]Hematologic Malignancies ResearchInstitute, City of Hope National MedicalCenter, Los Angeles, CA 91010, USA [5]Comprehensive Cancer Center, City ofHope, Los Angeles, CA 91010, USA [6]Department of Immuno-Oncology,Beckman Research Institute, LosAngeles, CA 91010, USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号